Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:59
|
Bid Volume |
Ask
02/27/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
41.10
-2.64
(
-6.04% )
|
41.03
|
9,400 |
41.19
|
1,100 |
Analysis date: 24.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 24.02.2026.
Interest
None
None
No stars since 06.02.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 09.01.2026 at a price of 53.25.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 06.02.2026.
4wk Rel Perf
-15.92%
-15.92%
The four-week dividend-adjusted underperformance versus SP500 is 15.92%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.00%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.78%.
Mkt Cap in $bn
4.56
4.56
With a market capitalization between $2 & $8bn, CRINETICS PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
0.14
0.14
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-10.67
-10.67
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
1.53%
1.53%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
12
12
Over the last seven weeks, an average of 12 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
100
100
For 1% of index variation, the stock varies on average by 1.00%.
Correlation
0.32
0.32
Stock movements are strongly independent of index variations.
Value at Risk
16.70
16.70
The value at risk is estimated at USD 16.70. The risk is therefore 37.50%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
04.02.2025
04.02.2025